Abstract
Background Cortical thickness reductions are evident in patients with schizophrenia. Associations between antipsychotic medications (APMs) and cortical morphometry have been explored in schizophrenia patients. This raises the question of whether the reconfiguration of morphological architecture by APM plays potential compensatory roles for abnormalities in the cerebral cortex.
Methods Structural MRI were obtained from 127 medication-naive first-episode schizophrenia (FES) patients and 133 matched healthy controls. Patients received 12 weeks of APM and were categorized as responders (n=75) or nonresponders (n=52) at follow-up. Using surface-based morphometry and structural covariance analysis, this study investigated the short-term effects of antipsychotics on cortical thickness and cortico-cortical connectivity. Global efficiency was computed to characterize network integration of the large-scale structural connectome. The relationship between connectivity and cortical thinning was examined by the structural covariance analysis among top-n regions with thickness reduction.
Results Widespread cortical thickness reductions were observed in pre-APM patients. Post-APM patients showed more reductions in cortical thickness, even in the frontotemporal regions without baseline reductions. Covariance analysis revealed strong cortico-cortical connectivity and higher network integration in responders than in nonresponders. Notably, the nonresponders lacked key nodes of the prefrontal and temporal regions for the covariance network between top-n regions with cortical thickness reductions.
Conclusions Antipsychotic effects are not restricted to a single brain region but rather exhibit a network-level covariance pattern. Neuroimaging connectomics highlights the positive effects of antipsychotics on the reconfiguration of brain architecture, suggesting that abnormalities in regional morphology may be compensated by increasing interregional covariance when symptoms are controlled by antipsychotics.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is an observational study, not a randomized clinical trial
Funding Statement
This work was partly supported by the grant from the National Key R&D Program of China (No. 2018YFA0701400), grants from the National Natural Science Foundation of China (No. grant number: 61933003, 81771822, 81861128001, and 81771925), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-5-039) and the Project of Science and Technology Department of Sichuan Province (No. 2019YJ0179).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of Shanghai Mental Health Center. All subjects/patients signed written informed consent forms.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
